|
GB201900031D0
|
|
Antibacterial oral compositions
|
|
AU2018293307A1
|
|
Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
|
|
EP3292758A1
|
|
Antimicrobial composition comprising a carboxylic acid and two diols
|
|
EP3117825A1
|
|
Oral formulation comprising berberine and morus alba extract
|
|
JP2013056925A
|
|
Combination of andolast/glucocorticoid
|
|
HUE026775T2
|
|
A nutraceutical compound for treating excess of weight
|
|
CA2776222A1
|
|
Hyaluronic acid esters, their preparation and use in dermatology
|
|
AU2011101558A4
|
|
Crystalline forms of 6-(1H-imadazol-1-YL)-2-phenylquinazoline
|
|
CN103702980A
|
|
Cyclic amine derivatives as EP4 receptor antagonists
|
|
EP2484674A1
|
|
Spiro aminic compounds with NK1 antagonist activity
|
|
WO2012076063A1
|
|
Pyridine amide derivatives as ep4 receptor antagonists
|
|
EP2236127A1
|
|
A composition for intimate hygiene
|
|
EP2275421A1
|
|
Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
|
|
CN102159208A
|
|
6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands
|
|
US2010028395A1
|
|
Compositions containing n-acetylglucosamine for use in dermo-cosmetology and aesthetic medicine
|
|
CA2715796A1
|
|
2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain
|
|
EP1889615A2
|
|
Formulations for oral administration with a health promoting effect on the osteoarticular and muscleskeleton apparatus
|
|
EP2007429A1
|
|
Oral formulation with beneficial cardiovascular effects, comprising berberine
|
|
EP1940376A2
|
|
Use of neboglamine in the treatment of toxicodependency
|
|
EP2066653A1
|
|
6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
|
